Walmart Boosts Benefits: Free Meds & More for Employees

Walmart is set to implement a substantial overhaul of its employee benefits package beginning in 2027. The company's updated plan includes no-cost coverage for more than 250 prescription drugs. This comprehensive list features certain insulins, inhalers, and notably, GLP-1 medications like Ozempic and Mounjaro for employees diagnosed with Type 2 diabetes, though these will require prior authorization.

In addition to prescription drug coverage, Walmart is expanding access to specialized medical care. Employees facing serious diagnoses will benefit from enhanced access to specialists through partnerships with renowned institutions like the Mayo Clinic and Cleveland Clinic. Starting in 2026 for cancer treatment and second opinions, this benefit will extend to rare conditions and neurological diseases such as ALS, multiple sclerosis, and Parkinson's disease in 2027.

Parental support is also a key focus, with Walmart introducing up to 12 weeks of paid leave for parents whose newborns require a neonatal intensive care unit (NICU) stay. This leave can be combined with existing parental and maternity leave, offering crucial flexibility during challenging times. The cost of Walmart's starting employee health plan will see a modest increase of $1.50 per pay period, bringing the total to $39.80.

These extensive benefit enhancements are strategically designed to reduce employee turnover across Walmart's vast U.S. workforce of approximately 1.6 million. By investing in worker well-being and financial security, the company anticipates significant savings in recruiting and onboarding costs. The decision to cover GLP-1 medications for diabetes while excluding weight-loss indications reflects a careful approach to managing rising drug costs and is expected to influence other large employers.